SHARE

The global blood screening market revenue is expected to expand at a moderate CAGR over the forecast period. Increasing technological advancements in blood screening technologies and increasing prevalence of infectious diseases are key factors expected to drive growth of the blood screening market over the forecast period.

The global blood screening blood screening market report has been segmented on the basis of technology, product, and region. On the basis of technology, the target market is segmented into nucleic acid amplification test (NAT), enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA) and enzyme immunoassay (EIA), next-generation sequencing (NGS), and western blotting. The nucleic acid amplification test (NAT) technology segment is expected to register significant share in terms of revenue over the forecast period, owing to its high sensitivity. On the basis of product, the target market is segmented into reagent and instrument. The reagent application segment is expected to register highest share in terms of revenue over the forecast period, owing to its Level of accuracy and ability to detect presence and type of various elements form the available sample.

Request for the Sample Report Here: https://marketresearch.biz/report/blood-screening-market/request-sample/

Based on the region the blood screening blood screening market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is estimated to be highest share in terms of revenue over the forecast period, owing to technological advancements and rising adoption of new technologies in various countries in this region. The market in Asia Pacific is expected to register moderate growth of CAGR in terms of revenue, owing to increasing government initiatives for spreading awareness about safety of blood donation and increasing patient pool in developing countries such as India and China in the region.

Key players operating in the global blood screening blood screening market include Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Ortho-Clinical Diagnostics, Inc., Danaher Corporation (Beckman Coulter, Inc.), Abbott Laboratories, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Beckman Coulter, Inc., and Roche Diagnostics Corporation.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here